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Background: Adults with cystic ﬁbrosis (CF) have altered large artery haemodynamics which is associated with a persisting systemic inﬂammatory
state. We hypothesized that a short-term intervention favorably inﬂuencing the inﬂammatory status may modify their haemodynamic state.
Methods: Adult patients with CF were studied immediately preceding and following 2 weeks of intravenous antibiotics. Large artery haemodynamics,
principally heart rate-adjusted augmentation index (AIx) were obtained. Blood pressure (BP), spirometry and CRP were also measured.
Results: Complete data was available for 15 patients; mean (SD) age 28 (6)years. CRP was reduced while FEV1% predicted improved. Following
treatment AIx was lower: 10.9 (10.9)% to 8.1 (10.9)% (pb0.05) while BP was similar and a trend toward lower heart rate (p=0.06). Change in AIx
was related to baseline FEV1% predicted (r=0.77) and BMI (r=0.71) (both Pb0.01).
Conclusion: The abnormal central haemodynamics evident in adults with CF is modulated with a short intervention of intravenous antibiotics.
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Arterial; Stiffness; Inﬂammation; Cystic ﬁbrosis; Blood pressure; Vascular1. Introduction
Adult patients with cystic fibrosis (CF) have evidence of
haemodynamic alterations within the systemic circulation as
depicted by an increase in the vascular parameter, augmentation
index (AIx) [1,2]. These alterations are evident at clinical
stability [1], appear exaggerated during light exercise [3] and
may have deleterious consequences for myocardial work and
perfusion of target organs, such as the brain and kidney [4].⁎ Corresponding author at: Department of Clinical Pharmacology, Division of
Biomedical Sciences, St George's Hospital, Tooting, London, SW17 0RE, UK.
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doi:10.1016/j.jcf.2012.07.004Themechanisms underlying increased AIx, a marker of loading
or ‘stress’ on the central systemic vasculature, in the CF population
are currently unclear. A predictive relationship between circulating
C-reactive protein (CRP) and AIx, suggests that systemic
inflammation may be relevant [1], although not demonstrating
causation. A similar relationship is apparent in cross-sectional
studies in both healthy individuals [5] and patients with chronic
inflammatory disorders [6–9]. In the general population the nature
of this relationship is furthered by the finding that an acute
pro-inflammatory stimulus such as vaccination is associated with
heightened vessel stiffness [10], whereas, anti-inflammatory
therapy can favorably alter large artery haemodynamics. More
specifically, anti-tumor necrosis factor alpha (TNFα) is associated
with reductions in both AIx and aortic pulse wave velocity
(APWV) in rheumatoid arthritis [6,11,12].by Elsevier B.V. All rights reserved.
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characterized by the presence of persistent systemic inflammation
that may increase periodically at times of ‘exacerbation’, i.e. in
association with clinical deterioration. In CF, intervention with
intravenous (iv) antibiotics is recognized to attenuate circulating
markers of inflammation and result in parallel improvements in
clinical characteristics; including pulmonary function, body mass
[13–15] as well as reduction in energy expenditure, circulating
catecholamine levels and catabolic metabolism [14–16].
Currently there is little detail available regarding the
haemodynamic response to treatment with iv antibiotics in the
CF population. Studies detail a reduction in heart rate (HR)
[15,17,18], however there are no data available concerning
alterations in blood pressure or large artery haemodynamics. This
latter is important given the implications of altered large artery
haemodynamics for cardiovascular health and more specifically
for myocardial work and perfusion of the distal organs.
The aim of this study therefore was to evaluate the effect of a
two-week course of iv antibiotics on large artery haemodynamics
in a cohort of adults with CF. We hypothesized that in addition to
the improvement in standard clinical parameters, there would be
an associated improvement in large artery haemodynamics
following iv antibiotic treatment.
2. Methods
2.1. Participants
Adult patients with CF (clinical features and positive sweat
test and/or an accepted CF genotype) were recruited from
consecutive patients attending Frimley Park Hospital at a time of
initiation of iv antibiotic treatment for an exacerbation in
respiratory symptoms. Decision to initiate antibiotic treatment
and thus definition of ‘exacerbation’ as well as selection of
antibiotic therapy were made by the physician in charge and
independent to the study investigator.
Initiation of oral corticosteroid therapy was an exclusion factor
given its potential to confound vascular and inflammatory
measures, however those patients on a regular daily dose were
not excluded provided the dose was unaltered throughout the
study period.
2.2. Ethical statement
The study was approved by the Surrey Research Ethics
Committee, National Research Ethics Service, Education
Centre, Royal Surrey County Hospital (Surrey, UK—07/
Q1909/82). All subjects provided written informed consent.
2.3. Study design
Subjects were required to attend on two occasions; at onset of
symptoms and prior to initiation of iv antibiotics (visit 1) and
following 2 weeks of treatment (visit 2). At each visit, subjects
were requested to abstain from caffeinated beverages and tobacco
prior to assessment. Patients were also requested to abstain from
inhaled short acting ß-2 agonists prior to visit on the day ofassessment. Patients were advised to administer other medica-
tions according to their usual routine but to adhere to the same
medication regime (i.e. timing and dose) for both visits.
Study assessments were planned to take place at the same time
of day and with similar timing of dietary intake prior to
assessment with no food to be consumed in the 2 h prior to
assessment. All patients classified as having CF related diabetes
(CFRD) [19] were on treatment with regular subcutaneous
insulin therapy and were advised to administer subcutaneous
insulin in accordancewith their usual regime but not within 2 h of
haemodynamic measurement.
2.4. Visit assessment
Height and weight were measured and BMI (kg/m2) was
calculated. Peripheral oxygen saturation (SpO2) and temperature
were measured. Subjects then underwent haemodynamic mea-
surements following 10 min of supine rest. Forced expiratory
volume in 1 s (FEV1) and vital capacity (FVC) were determined
by spirometry [20] and venous blood was collected.
2.5. Haemodynamic assessment
Measurements were taken, in a quiet temperature controlled
laboratory. Peripheral blood pressure (BP), the mean of three
consecutive brachial artery readings, was measured (OMRON
Corporation, Japan). Radial artery waveforms were recorded
using a high fidelity micromanometer (Millar instruments, Texas,
USA) as described previously [1]. In brief, radial artery
waveforms were recorded and analyzed using pulse wave
analysis (SphygmoCor, AtCor Medical, Sydney, Australia) to
generate a corresponding central arterial waveform and calculate
AIx, normalized to a HR of 75 beats per minute. Brachial and
APWV were determined by sequentially recording ECG gated
radial, carotid and femoral artery waveforms [21].
2.6. Laboratory analyses
Venous blood was collected for determination of high
sensitivity C-reactive protein (CRP), serum creatinine and sodium
(Na+) by standard methods in an accredited laboratory (ADVIA
2400, SiemensMedical solutions). Estimated glomerular filtration
rate (GFR) was determined [22].
2.7. Statistical analysis
Data is reported as arithmetic mean (SD), unless otherwise
stated. Positively skewed data (CRP) was log10 transformed and
reported as geometric mean (SD). A two-sided paired t-test was
used to evaluate differences in continuous normally distributed
variables between the visits with relationships assessed using
Pearson's correlation coefficient. Continuous variables that did
not conform to a normal distribution (SpO2) were evaluated using
non-parametric tests (Wilcoxon signed ranks test and Spearman's
correlation coefficient). Analysis was performed using SPSS v 15
(SPSS Inc., Chicago, USA) and GraphPad (Prism v. 5, GraphPad
Software Inc, USA) with a p-value of b0.05 considered
Table 2
Haemodynamic data.
Variable Visit 1 Visit 2 p-value
Heart rate (bpm) 75 (15) 70 (12) 0.06
PSBP (mm Hg) 121 (10) 123 (10) 0.21
PDBP (mm Hg) 73 (8) 74 (9) 0.71
PPP (mm Hg) 48 (10) 47 (12) 0.79
PMAP (mm Hg) 89 (9) 90 (8) 0.69
AIx (%) 10.9 (10.9) 8.1 (10.9) 0.04
AP (mm Hg) 3.6 (4.0) 3.4 (3.5) 0.64
CSBP (mm Hg) 106 (9) 108 (9) 0.20
CDBP (mm Hg) 75 (9) 76 (7) 0.41
CPP (mm Hg) 31 (6) 32 (7) 0.52
CMAP (mm Hg) 85 (9) 87 (7) 0.28
PPA (PPP:CPP) 1.55 (0.19) 1.54 (0.18) 0.54
Brachial PWV (m/s) 8.6 (1.2) 8.6 (1.4) 0.74
APWV (m/s) 6.3 (1.0) 6.1 (1.1) 0.16
Data presented as mean (SD).
Definition of abbreviations; AIx, heart rate adjusted augmentation index; AP,
augmented pressure; APWV, aortic pulse wave velocity; BP, blood pressure;
CDBP, central diastolic BP; CSBP, central systolic BP; CPP, central pulse
pressure; MAP, mean arterial pressure; PDBP, peripheral diastolic BP; PPP,
peripheral pulse pressure; PPA, pulse pressure amplification; PSBP, peripheral
systolic BP; PWV, pulse wave velocity.
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change in haemodynamic parameters in a subgroup of patients
with an elevated CRP, defined as N5 mg/L (i.e. above upper limit
of normal) at visit 1.
3. Results
3.1. Subject characteristics, clinical and laboratory measures
Eighteen patients were recruited, however 15 were included in
final analysis (Table 1); one subject commenced iv corticosteroid
therapy between visits and one subject was isolated for influenza
H1N1 infection. It was not possible to collect any haemodynamic
data in one patient due to frequent extra-systolic beats.
Of these 15 subjects (7 males), mean (SD) age 28 (6)years,
range 16–38 years; 11 were homozygous for F508del while 4
patients were compound heterozygous for F508del and another
accepted CF mutation. Fourteen patients were pancreatic
insufficient and four were classified as having CFRD. All
patients had positive respiratory specimen isolates for either
Pseudomonas aeruginosa (n=14) or Staphylococcus aureus (n=
1) in the year prior to study inclusion. All patients reported an
increase in productive cough and systemic symptoms at the time
of initiation of iv antibiotics. All patients had a temperature of
b38 °C at both visits.
Intravenous antibiotic therapy was administered in the
outpatient setting in all but one case and included combinations
of the following antibiotics; tobramycin (n=10), colistin (n=7),
ceftazidime (n=5), meropenem (n=5), aztreonam (n=1), tazocin
(n=1) and gentamicin (n=1). There was no difference in SpO2
between visits (p=0.14). No patients were on or commenced oral
diabetic, anti-hypertensive, vasodilators or cholesterol lowering
medication. The majority of patients (n=13) were taking
azithromycin regularly and three patients were prescribed
corticosteroid (all ≤10 mg prednisolone daily).
Visits 1 and 2 were separated by a median (range) of 14
(13–16)days. Pulmonary function and BMI were greater
following iv antibiotics (Table 1), which were received for a
minimum of 13 days in all patients. The CRP reduced fromTable 1
Subject characteristics (n=15).
Variable Visit 1 Visit 2 p-value
Height (m) 1.69 (0.11) – –
Weight (kg) 61.0 (13.1) 61.6 (13.5) 0.006
BMI (kg/m2) 21.2 (2.4) 21.4 (2.4) 0.007
FEV1 (L) 2.1 (1.0) 2.3 (1.0) 0.02
FEV1% predicted 54.5 (19.7) 60.3 (19.6) 0.02
FVC (L) 3.1 (1.4) 3.4 (1.3) 0.01
FVC% predicted 67.3 (21.0) 75.7 (19.3) 0.01
SpO2 (%)⁎ 97 (81–99) 97 (91–100) 0.14
GFR (mL/min) 91.7 (24.8) 89.3 (27.7) 0.42
Na+ (mmol/L) 138 (3.0) 139 (3.0) 0.14
CRP (mg/L)# 6.9 (6.4) 2.6 (7.6) 0.03
Data presented as mean (SD) unless #Geometric mean (SD) or *median (range).
Definition of abbreviations; BMI, body mass index; CRP, C-reactive protein.
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GFR,
glomerular filtration rate; SpO2, oxygen saturation.visits 1 to 2 (p=0.03) while estimated GFR and serum Na+
were unchanged (Table 1).
3.2. Haemodynamic results
There was a trend for HR to be lower following treatment
(p=0.06) but no significant difference in peripheral or central
BP parameters (Table 2). Likewise brachial PWV (p=0.74) and
APWV (p=0.16) were similar between visits. However, the
primary variable, mean (SD) AIx was lower at visit 2; 8.1
(10.9)% than visit 1; 10.9 (10.9)% (p=0.04) (Fig. 1 and
Table 2). A reduction in AIx between visits was also apparent
when subjects with CFRD (n=4) were excluded from analysis;
8.9 (11.5)% to 5.3 (9.9%) (p=0.02).
The change in AIx was not related to AIx at first visit (p=
0.45). There was a direct relationship between change in AIx
and visit 1 FEV1% predicted (r=0.77) (Fig. 2) and BMI (r=
0.71, both pb0.01), such that a post treatment reduction in AIx
was most apparent in those patients with the worst clinical
status at first visit. There was however no association betweenFig. 1. Augmentation index (AIx) at visit 1 and visit 2.
Fig. 2. Relationship between change in augmentation index (AIx) following
intravenous antibiotics and forced expiratory volume in 1 s (FEV1) % predicted
at visit 1 (r=0.77, p=0.001). = subjects with reduction in AIx between visits.
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(p=0.69).
Circulating CRP was greater than 5 mg/L at visit 1 in eleven
patients (73%). When this group was analyzed separately there
were improvements in lung function, BMI and log10CRP
following iv antibiotics, and a reduction in AIx of −3.5 (4.6)%
(p=0.03). There was, again, no difference in any other central or
peripheral haemodynamic parameters.
4. Discussion
This is the first study to evaluate the influence of a therapeutic
intervention on central haemodynamic parameters in subjects
with CF. Following 2 weeks of iv antibiotics, we found a
significant reduction in AIx in the presence of a stable BP. This
was associated with improvements in clinical status and systemic
inflammation and suggests that overall there is modulation of
systemic vascular function in this setting.
The current study was designed to evaluate changes in large
artery haemodynamics with clear focus on the vascular parameter
AIx. This was on the background of our prior work describing
increased AIx in patients with CF at clinical stability [1] and
further affected during exercise [3] and given the fact that
population studies indicate that AIx is more closely related to
cardiovascular risk factors in young individuals than alternative
haemodynamic parameters [23,24]. We now report a magnitude
of reduction in AIx that is similar to that witnessed in response to
therapeutic intervention in other disorders characterized by
chronic systemic inflammation. Specifically, Galarraga et al.
[11] reported an approximately 3% absolute fall in AIx in patients
with rheumatoid arthritis in response to 4 months of anti-TNF-α
treatment. Similarly Van Doornum et al. [25] reported a fall of
approximately 4% following 3 months of statin therapy in
patients with inflammatory arthropathy.
The mechanisms underlying the response in large arterial
haemodynamics we report remain unclear and this study was not
designed to specifically characterize them. Several factors are
likely to interplay to modulate systemic arterial behavior in this
context, including the action of circulating and local mediators on
endothelial and vascular smoothmuscle function [10]. In additionit is apparent that an acute pro-inflammatory stimulus can
promote haemodynamic changes indicative of increased loading
on the central systemic vasculature [10]. In the current study we
did not specifically evaluate prospective changes in large artery
haemodynamics in response to a pro-inflammatory stimulus. We
did however demonstrate a response in haemodynamics to a
therapy recognized to favorably modulate systemic inflamma-
tion. In this respect the design of the current study was in keeping
with others, using this pragmatic approach to indirectly evaluate
the impact of an exacerbation and its treatment on physiological,
metabolic and biochemical parameters [15,18].
It is yet to be determined whether a response in large artery
haemodynamics to this intervention may have been more marked
in the presence of a greater pro-inflammatory change at initiation
of therapy. Certainly our study population contrasts with that
reported by Bell et al. [15], where patients were almost
universally hospitalized for treatment and had a mean CRP of
26 mg/L at initiation of therapy. While it is recognized that the
magnitude of systemic inflammatory response may not always
reflect symptomatic deterioration and requirement for iv
antibiotics in patients with CF, it may be that more pronounced
evidence of systemic inflammation at initiation of therapy is
associated with a greater impact on systemic vascular function.
In addition, other factors are also likely to be pertinent to the
changes in vascular function observed. Certainly, in the study by
Bell and colleagues [15] in patients with CF, treatment with iv
antibiotic therapy was associated with a reduction in plasma
norepinephrine. We did not determine catecholamine levels;
however it seems possible that similar changes indicative of a
heightened sympathoadrenal drive may account for the changes in
AIx we report.
In the studies evaluating the large artery haemodynamic
response to therapeutic intervention in patients with rheumatoid
arthritis, a consistent finding is that the greatest reduction in AIx is
apparent in patients with the highest disease activity scores at
baseline [25]. A similar relationship was evident in the current
study; with an apparent direct association between markers
commonly used to evaluate disease severity (i.e. FEV1 and
BMI) at first visit and change in AIx. It therefore appears that the
response of AIx to iv antibiotic therapy may be more pronounced
in patients with severe disease and further work is needed to
address this possibility.
The physiological and clinical significance of this magnitude
of reduction in AIx is unclear. As outlined in our previous work,
AIx provides an indication of the stress placed on the central
vasculature and as such may be taken as a surrogate indicator of
left ventricular loading and myocardial perfusion; with evidence
of long term associations for adverse cardiovascular outcome in
selected populations [26,27]. The magnitude of reduction in AIx
we observed following treatment is comparable to differences
attributed to the presence of the metabolic syndrome on
haemodynamic markers [24]. To date however there is no data
demonstrating that a short-term reduction in AIx translates into
significant changes in allied physiological measures (e.g. cardiac
function) or clinical outcome. Accordingly, investigators [25]
have been guarded in drawing conclusions regarding the
physiological or clinical implications of changes in AIx for
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little further interpretation in this context until the studies are
replicated with larger numbers and related to other physiological
measures in the longer term.
4.1. Limitations
A number of factors may complicate the interpretation of
changes in haemodynamic parameters in the setting of this
repeated measure design. We attempted to control for a number
of factors such as hydration and nutritional status, degree of
hypoxaemia, consumption of caffeinated beverages, changes in
timing of mediations and alterations in psychological stress by
providing detailed and clear information for patients and by
replicating the methodological approach at both visits. Further-
more, prior work within in our laboratory has demonstrated good
intra-observer reproducibility of applanation tonometry to
determine AIx in patients with CF by the same operator (mean
difference of 0.7% in AIx in 14 subjects studied on two occasions
separated by 2 weeks [unpublished work—J.H. PhD]).
Antibiotic selection was made by the physician in charge of
care based upon the sensitivity of prior bacterial isolates, previous
clinical response and medication intolerance/contra-indication
and it is conceivable that differences in antibiotic regime may
account for differences in haemodynamic response observed
between study subjects. To address this future studies would need
to evaluate response to a specific treatment protocol.
In conclusion, the current study extends understanding of
peripheral and central haemodynamics in the CF population
during a period of change in clinical status. In particular by
demonstrating that central systolic loading may be modified by
the use of iv antibiotic treatment in adults with CF across a broad
range of disease severity. The mechanisms underlying these
changes and implications for long-term cardiovascular health in
this population are priority areas for future research.
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